Laporan Laba Rugi (TTM)
Laporan Laba Rugi CRISPR Therapeutics AG - Depositary Receipt (Common Stock) menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.
Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.
|
2020 09-30 |
2020 12-31 |
2021 03-31 |
2021 06-30 |
2021 09-30 |
2021 12-31 |
2022 03-31 |
2022 06-30 |
2022 09-30 |
2022 12-31 |
2023 03-31 |
2023 06-30 |
2023 09-30 |
2023 12-31 |
2024 03-31 |
2024 06-30 |
2024 09-30 |
2024 12-31 |
2025 03-31 |
2025 06-30 |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 77 | 1 | 1 | 902 | 902 | 915 | 915 | 15 | 14 | 1 | 100 | 170 | 170 | 371 | 272 | 202 | 203 | 37 | 38 | 38 |
| Change (%) | -99.07 | 53.13 | 81,803.54 | 0.07 | 1.39 | 0.04 | -98.38 | -4.93 | -91.50 | 8,268.78 | 69.66 | -0.06 | 118.35 | -26.80 | -25.57 | 0.30 | -81.60 | 0.97 | 1.00 | |
| % of Revenue | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 |
| Cost Of Sales | 233 | 269 | 303 | 354 | 389 | 442 | 500 | 547 | 596 | 572 | 565 | 554 | 513 | 518 | 499 | 485 | 464 | 431 | 438 | 421 |
| Change (%) | 15.46 | 12.59 | 16.79 | 9.87 | 13.50 | 13.20 | 9.37 | 9.05 | -4.11 | -1.18 | -1.94 | -7.46 | 0.93 | -3.67 | -2.79 | -4.29 | -7.11 | 1.59 | -3.94 | |
| % of Revenue | 301.61 | 37,469.68 | 27,549.32 | 39.28 | 43.13 | 48.28 | 54.63 | 3,690.16 | 4,232.74 | 47,737.48 | 563.68 | 325.79 | 301.65 | 139.43 | 183.50 | 239.68 | 228.71 | 1,154.80 | 1,161.93 | 1,105.15 |
| Gross Operating Profit | -156 | -269 | -302 | 548 | 513 | 473 | 415 | -532 | -582 | -571 | -465 | -384 | -343 | -146 | -227 | -282 | -261 | -394 | -400 | -382 |
| Change (%) | 72.26 | 12.48 | -281.17 | -6.26 | -7.80 | -12.24 | -228.13 | 9.44 | -2.00 | -18.54 | -17.38 | -10.74 | -57.30 | 55.00 | 24.50 | -7.58 | 50.76 | 1.65 | -4.41 | |
| % of Revenue | -201.61 | -37,369.68 | -27,449.32 | 60.72 | 56.87 | 51.72 | 45.37 | -3,590.16 | -4,132.74 | -47,637.48 | -463.68 | -225.79 | -201.65 | -39.43 | -83.50 | -139.68 | -128.71 | -1,054.80 | -1,061.93 | -1,005.15 |
| SG&A | 80 | 86 | 93 | 100 | 102 | 100 | 103 | 102 | 105 | 102 | 97 | 90 | 81 | 76 | 72 | 72 | 71 | 73 | 74 | 74 |
| Change (%) | 7.57 | 8.66 | 6.90 | 2.18 | -2.05 | 3.51 | -1.47 | 3.24 | -2.39 | -5.52 | -7.48 | -9.73 | -5.80 | -5.79 | 0.63 | -1.21 | 2.31 | 1.84 | -0.76 | |
| % of Revenue | 103.04 | 11,925.87 | 8,462.76 | 11.05 | 11.28 | 10.90 | 11.27 | 686.06 | 744.96 | 8,552.92 | 96.55 | 52.65 | 47.56 | 20.52 | 26.41 | 35.70 | 35.17 | 195.58 | 197.27 | 193.84 |
| R&D | ||||||||||||||||||||
| Change (%) | ||||||||||||||||||||
| % of Revenue | ||||||||||||||||||||
| OpEx | 313 | 355 | 396 | 454 | 491 | 541 | 603 | 649 | 701 | 674 | 662 | 644 | 594 | 594 | 570 | 557 | 535 | 504 | 512 | 494 |
| Change (%) | 13.45 | 11.64 | 14.46 | 8.18 | 10.28 | 11.42 | 7.51 | 8.14 | -3.86 | -1.84 | -2.75 | -7.78 | 0.01 | -3.94 | -2.36 | -3.89 | -5.86 | 1.63 | -3.48 | |
| % of Revenue | 404.65 | 49,395.55 | 36,012.08 | 50.33 | 54.40 | 59.18 | 65.90 | 4,376.22 | 4,977.71 | 56,290.40 | 660.23 | 378.45 | 349.20 | 159.95 | 209.91 | 275.39 | 263.88 | 1,350.38 | 1,359.20 | 1,298.98 |
| Operating Income | -236 | -354 | -395 | 448 | 411 | 374 | 312 | -634 | -687 | -673 | -562 | -474 | -424 | -223 | -299 | -355 | -332 | -467 | -474 | -456 |
| Change (%) | 50.38 | 11.56 | -213.28 | -8.14 | -9.22 | -16.45 | -303.07 | 8.45 | -2.06 | -16.56 | -15.67 | -10.55 | -47.47 | 34.20 | 18.76 | -6.28 | 40.36 | 1.68 | -3.83 | |
| % of Revenue | -304.65 | -49,295.55 | -35,912.08 | 49.67 | 45.60 | 40.82 | 34.10 | -4,276.22 | -4,877.71 | -56,190.40 | -560.23 | -278.45 | -249.20 | -59.95 | -109.91 | -175.39 | -163.88 | -1,250.38 | -1,259.20 | -1,198.98 |
| Interest Expense | -2 | |||||||||||||||||||
| Change (%) | ||||||||||||||||||||
| % of Revenue | -0.17 | |||||||||||||||||||
| Net Income | -211 | -349 | -392 | 447 | 412 | 378 | 312 | -633 | -681 | -650 | -524 | -416 | -354 | -154 | -217 | -266 | -240 | -366 | -386 | -468 |
| Change (%) | 65.12 | 12.45 | -213.84 | -7.77 | -8.31 | -17.49 | -303.29 | 7.48 | -4.51 | -19.40 | -20.63 | -15.00 | -56.55 | 41.36 | 22.41 | -9.86 | 52.86 | 5.30 | 21.30 | |
| % of Revenue | -273.10 | -48,520.86 | -35,630.97 | 49.52 | 45.64 | 41.28 | 34.04 | -4,274.02 | -4,831.79 | -54,271.70 | -522.67 | -244.52 | -207.95 | -41.38 | -79.91 | -131.44 | -118.13 | -981.54 | -1,023.64 | -1,229.43 |
Source: Capital IQ
